NASDAQ:CLNN Clene (CLNN) Stock Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free CLNN Stock Alerts $0.34 +0.01 (+2.20%) (As of 12:34 PM ET) Add Compare Share Share Today's Range$0.33▼$0.3650-Day Range$0.31▼$0.5052-Week Range$0.25▼$1.09Volume296,743 shsAverage Volume964,124 shsMarket Capitalization$44.23 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Clene alerts: Email Address Clene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,787.3% Upside$6.50 Price TargetShort InterestHealthy0.12% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$8,775 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.33) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector383rd out of 907 stocksPharmaceutical Preparations Industry169th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClene has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the outstanding shares of Clene have been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 8.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Clene this week, compared to 2 articles on an average week.Search InterestOnly 10 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Clene to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,775.00 in company stock.Percentage Held by Insiders25.10% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.28% of the stock of Clene is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to grow in the coming year, from ($0.33) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Clene Stock (NASDAQ:CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More CLNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLNN Stock News HeadlinesApril 23, 2024 | finance.yahoo.comBullish Clene Insiders Loaded Up On US$9.58m Of StockApril 18, 2024 | americanbankingnews.comClene's (CLNN) Buy Rating Reaffirmed at HC WainwrightApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | benzinga.comThe Analyst Verdict: Clene In The Eyes Of 5 ExpertsApril 16, 2024 | msn.comClene stock rallies 52% post-market on MS drug dataApril 16, 2024 | globenewswire.comEvidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual MeetingMarch 27, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MSMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 19, 2024 | finance.yahoo.comIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob EtheringtonMarch 17, 2024 | morningstar.comClene Inc Ordinary SharesMarch 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market DynamicsMarch 15, 2024 | globenewswire.comClene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®March 13, 2024 | finanznachrichten.deClene Inc.: Clene Reports Full Year 2023 Financial Results and Recent Operating HighlightsMarch 13, 2024 | markets.businessinsider.comBreaking Down Clene: 4 Analysts Share Their ViewsMarch 13, 2024 | benzinga.comClene: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comClene Reports Full Year 2023 Financial Results and Recent Operating HighlightsMarch 7, 2024 | finance.yahoo.comClene to Present at the 36th Annual ROTH ConferenceFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical OutcomesFebruary 29, 2024 | globenewswire.comClene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024February 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amidst Strong Clinical Data and Financial StabilityFebruary 22, 2024 | markets.businessinsider.comClene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use ProgramsFebruary 17, 2024 | finance.yahoo.comCLNN Mar 2024 1.000 putFebruary 17, 2024 | finance.yahoo.comCLNN Mar 2024 3.000 callFebruary 8, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive InterviewFebruary 6, 2024 | finance.yahoo.comIbogaine By David Dardashti Offers Free Online Support for Post-Treatment CareFebruary 6, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS ParticipantsSee More Headlines Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/25/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,828.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,500,000.00 Net Margins-7,569.42% Pretax Margin-7,569.42% Return on Equity-253.48% Return on Assets-62.88% Debt Debt-to-Equity Ratio0.53 Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual Sales$650,000.00 Price / Sales66.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.37Miscellaneous Outstanding Shares128,430,000Free Float96,197,000Market Cap$43.28 million OptionableOptionable Beta0.50 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Robert Etherington MBA (Age 57)CEO, President & Director Comp: $590.98kMr. Morgan R. Brown CPA (Age 56)M.B.A., Chief Financial Officer Comp: $374.05kMr. Mark G. Mortenson ESQ. (Age 66)Chief Science Officer Comp: $482.98kMr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryMr. Michael T. HotchkinChief Development OfficerMs. Mary Anne McneilHead of Human ResourcesDr. Benjamin M. Greenberg M.D.M.H.S., Head of MedicalMore ExecutivesKey CompetitorsApollomicsNASDAQ:APLMNextCureNASDAQ:NXTCBolt BiotherapeuticsNASDAQ:BOLTRockwell MedicalNASDAQ:RMTIAadi BioscienceNASDAQ:AADIView All CompetitorsInsiders & InstitutionsGeneral Resonance LlcSold 22,500 sharesTotal: $8,775.00 ($0.39/share)Simplex Trading LLCSold 50,400 shares on 2/2/2024Ownership: 0.000%Soltis Investment Advisors LLCSold 109,403 shares on 1/26/2024Ownership: 0.085%David J MatlinBought 250,002 shares on 11/10/2023Total: $102,500.82 ($0.41/share)John Henry StevensBought 316,455 shares on 6/26/2023Total: $253,164.00 ($0.80/share)View All Insider TransactionsView All Institutional Transactions CLNN Stock Analysis - Frequently Asked Questions Should I buy or sell Clene stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks. What is Clene's stock price target for 2024? 4 analysts have issued 12-month price objectives for Clene's shares. Their CLNN share price targets range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $6.50 in the next year. This suggests a possible upside of 1,787.3% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts. How have CLNN shares performed in 2024? Clene's stock was trading at $0.2966 at the start of the year. Since then, CLNN stock has increased by 16.1% and is now trading at $0.3444. View the best growth stocks for 2024 here. Are investors shorting Clene? Clene saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 148,500 shares, a decrease of 8.8% from the March 31st total of 162,900 shares. Based on an average trading volume of 913,500 shares, the short-interest ratio is presently 0.2 days. View Clene's Short Interest. When is Clene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CLNN earnings forecast. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company earned $0.17 million during the quarter, compared to the consensus estimate of $0.14 million. Clene had a negative net margin of 7,569.42% and a negative trailing twelve-month return on equity of 253.48%. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLNN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmith“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
